var data={"title":"Polyethylene glycol electrolyte solution: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Polyethylene glycol electrolyte solution: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6798?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=polyethylene-glycol-electrolyte-solution-patient-drug-information\" class=\"drug drug_patient\">see &quot;Polyethylene glycol electrolyte solution: Patient drug information&quot;</a> and <a href=\"topic.htm?path=polyethylene-glycol-electrolyte-solution-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Polyethylene glycol electrolyte solution: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211122\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Colyte;</li>\n      <li>GaviLyte-C;</li>\n      <li>GaviLyte-G;</li>\n      <li>GaviLyte-N;</li>\n      <li>GoLYTELY;</li>\n      <li>MoviPrep;</li>\n      <li>NuLYTELY;</li>\n      <li>TriLyte</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211123\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Colyte;</li>\n      <li>Klean-Prep;</li>\n      <li>PegLyte</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211139\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Laxative, Osmotic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211125\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Bowel cleansing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CoLyte, GaviLyte-C, GaviLyte-G, GaviLyte-N, GoLYTELY, NuLYTELY, TriLyte:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Oral: 240 mL (8 oz) every 10 minutes until 4 L are consumed or the rectal effluent is clear; rapid drinking of each portion is preferred to drinking small amounts continuously</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Nasogastric: 20-30 mL/minute until 4 L are administered or the rectal effluent is clear</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MoviPrep: Oral: Administer 2 L total with an additional 1 L of clear fluid prior to colonoscopy as follows:  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Split dose (2 day regimen) (preferred method): </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Dose 1: Evening before colonoscopy (10-12 hours before dose 2): 240 mL (8 oz) every 15 minutes until 1 L (entire contents of container) is consumed. Then fill container with 480 mL (16 oz) of clear liquid and consume prior to going to bed. </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Dose 2: On the morning of the colonoscopy (beginning at least 3.5 hours prior to procedure): 240 mL (8 oz) every 15 minutes until 1 L (entire contents of container) is consumed.  Then fill container with 480 mL (16 oz) of clear liquid and consume at least 2 hours before the procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Evening only dose (1 day regimen) (alternate method): </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Dose 1: Evening before colonoscopy (at least 3.5 hours before bedtime): 240 mL (8 oz) every 15 minutes until 1 L (entire contents of container) is consumed</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Dose 2:  ~90 minutes after starting dose 1: 240 mL (8 oz) every 15 minutes until 1 L (entire contents of container) is consumed. Then fill container with 1 L (32 oz) of clear liquid and consume all of the liquid prior to going to bed. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Whole bowel irrigation (off-label use; AACT, 2004):</b> Nasogastric: 1500-2000 mL/hour until the rectal effluent is clear. <b>Note:</b> Continue treatment at least until the rectal effluent is clear; treatment duration may be extended based on corroborative evidence of continued presence of poisons in the GI tract as determined by radiographic means or the presence of the poison in the effluent.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211134\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=polyethylene-glycol-electrolyte-solution-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Polyethylene glycol electrolyte solution: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Bowel cleansing:</b> Infants &ge;6 months, Children, and Adolescents: GaviLyte-N, NuLYTELY, TriLyte: Oral, Nasogastric: 25 mL/kg/hour  until the rectal effluent is clear (maximum total dose: 4 L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Whole bowel irrigation (off-label use; AACT, 2004):</b> Nasogastric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants &ge;9 months and Children &lt;6 years: 500 mL/hour until the rectal effluent is clear</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &ge;6 years: 1000 mL/hour until the rectal effluent is clear</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents: 1500-2000 mL/hour until the rectal effluent is clear</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Note:</b> Continue treatment at least until the rectal effluent is clear; treatment duration may be extended based on corroborative evidence of continued presence of poisons in the GI tract as determined by radiographic means or the presence of the poison in the effluent.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211126\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22448429\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling. Use with caution due to risks of fluid and electrolyte abnormalities.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22448430\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211104\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Powder, for solution, oral: PEG 3350 240 g, sodium sulfate 22.72 g, sodium bicarbonate 6.72 g, sodium chloride 5.84 g, and potassium chloride 2.98 g (4000 mL); PEG 3350 236 g, sodium sulfate 22.74 g, sodium bicarbonate 6.74 g, sodium chloride 5.86 g, and potassium chloride 2.97 g (4000 mL); PEG 3350 240 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, and potassium chloride 1.48 g (4000 mL); PEG 3350 420 g,  sodium bicarbonate 5.72 g, sodium chloride 11.2 g, and potassium chloride 1.48 g (4000 mL) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Colyte: PEG 3350 227.1 g, sodium sulfate 21.5 g, sodium bicarbonate 6.36 g, sodium chloride 5.53 g, and potassium chloride 2.82 g (3785 mL) [supplied with cherry, lemon lime, and orange flavor packs]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Colyte: PEG 3350 240 g, sodium sulfate 22.72 g, sodium bicarbonate 6.72 g, sodium chloride 5.84 g, and potassium chloride 2.98 g (4000 mL) [supplied with cherry, citrus berry, lemon lime, orange, and pineapple flavor packs]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GaviLyte-C: PEG 3350 240 g, sodium sulfate 22.72 g, sodium bicarbonate 6.72 g, sodium chloride 5.84 g, and potassium chloride 2.98 g (4000 mL) [supplied with lemon flavor packet]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GaviLyte-G: PEG 3350 236 g, sodium sulfate 22.74 g, sodium bicarbonate 6.74 g, sodium chloride 5.86 g, and potassium chloride 2.97 g (4000 mL) [supplied with lemon flavor packet]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GaviLyte-N: PEG 3350 420 g,  sodium bicarbonate 5.72 g, sodium chloride 11.2 g, and potassium chloride 1.48 g (4000 mL) [supplied with lemon flavor packet]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoLYTELY: PEG 3350 227.1 g, sodium sulfate 21.5 g, sodium bicarbonate 6.36 g, sodium chloride 5.53 g, and potassium chloride 2.82 g per packet (1s) [regular flavor; makes 1 gallon of solution after mixing]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoLYTELY: PEG 3350 236 g, sodium sulfate 22.74 g, sodium bicarbonate 6.74 g, sodium chloride 5.86 g, and potassium chloride 2.97 g (4000 mL) [regular and pineapple flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MoviPrep: Pouch A: PEG 3350 100g, sodium sulfate 7.5 g, sodium chloride 2.69 g, potassium chloride 1.02 g; Pouch B: Ascorbic acid 4.7 g, sodium ascorbate 5.9 g (1000 mL) [contains phenylalanine 131 mg/treatment; lemon flavor; packaged with 2 of Pouch A and 2 of Pouch B in carton and a disposable reconstitution container]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">NuLYTELY: PEG 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, and potassium chloride 1.48 g (4000 mL) [supplied with cherry, lemon-lime, orange, and pineapple flavor packs]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">TriLyte: PEG 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, and potassium chloride 1.48 g (4000 mL) [supplied with cherry, citrus berry, lemon lime, orange, and pineapple flavor packs] </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211090\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12808915\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">GoLYTELY: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM370635.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5Wd8Hdxs7P4TWhlGyV2cRdIw==&amp;TOPIC_ID=9789\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM370635.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">MoviPrep: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM253840.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV689pCzBsfS0zDVXju3jjAXVA==&amp;TOPIC_ID=9789\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM253840.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">NuLYTELY: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM370636.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5WyTYpqPI+HCyVv3fluBWY+A==&amp;TOPIC_ID=9789\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM370636.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211107\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;\">Oral: Rapid drinking of each portion is preferred to drinking small amounts continuously. No additional ingredients or flavors (other than the flavor packets provided) should be added to the polyethylene glycol-electrolyte solution. Chilling the solution may improve palatability; administration of a chilled solution is <b>not</b> recommended in infants. Oral medications should not be administered within 1 hour of start of therapy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Nasogastric administration: CoLyte, GaviLyte-C, GaviLyte-G, GaviLyte-N, GoLYTELY, NuLYTELY, TriLyte: The solution may be administered via nasogastric tube for bowel cleansing  and whole bowel irrigation (preferred route; off-label use) in patients who are unwilling or unable to drink the solution. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211105\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Bowel cleansing prior to colonoscopy or barium enema X-ray examination</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25470743\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Whole bowel irrigation for toxic ingestions</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211145\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GoLYTELY may be confused with NuLYTELY </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">TriLyte may be confused with TriLipix</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Polyethylene glycol 3350 may be confused with polyethylene glycol 4000 [international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211097\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Sleep disorder (35%; evening prep vs oral sodium phosphate solution [90 mL]), rigors (34%; evening prep vs oral sodium phosphate solution [90 mL]), malaise (18% to 27%; MoviPrep split dose vs 4 L PEG with electrolytes [18%]; evening dose vs oral sodium phosphate solution [90 mL] [53%])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Increased thirst (&lt;47%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Abdominal distention (&lt;60%; evening prep vs oral sodium phosphate solution [90 mL]), anorectal pain (&lt;52%; evening prep vs oral sodium phosphate solution [90 mL]), bloating (&le;50%), nausea (14% to &le;50%; split dose vs 4 L PEG with electrolytes [20%]; evening prep vs oral sodium phosphate solution [90 mL] [47%]), abdominal pain (6% to 39%; evening prep vs oral sodium phosphate solution [90 mL] [32%]; split dose vs PEG with electrolytes [6%]), hunger (30%; evening prep vs oral sodium phosphate solution [90 mL]), vomiting (7% to 12%; evening MoviPrep vs oral sodium phosphate solution (90 mL) [8%]; split dose vs PEG with electrolytes [13%])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Dizziness (3% to 7%; evening prep vs oral sodium phosphate solution [90 mL]), headache (2%; evening prep vs oral sodium phosphate solution [90 mL])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hypokalemia (children 0%; evening prep vs oral sodium phosphate solution [90 mL] [6%])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Dyspepsia (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Frequency not defined, postmarketing, and/or case reports: Abdominal cramps, anaphylaxis, angioedema, aspiration, asystole (older adults &gt;60 years), chest tightness, chills, dehydration, dermatitis, dyspnea, epigastric fullness, esophageal perforation (older adults &gt;60 years), facial edema, fever, flatulence, hypersensitivity reaction, ischemic colitis, lip edema, Mallory-Weiss syndrome (older adults &gt;60 years), pruritus, pulmonary edema (older adults &gt;60 years), rhinorrhea, seizure, shock, skin rash, tightness in chest and throat, tongue edema, upper gastrointestinal hemorrhage (older adults &gt;60 years), urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211110\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to polyethylene glycol or any component of the formulation; ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211094\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Arrhythmias: Serious arrhythmias have been reported (rarely) with the use of ionic osmotic laxative products. Use with caution in patients who may be at risk of  cardiac arrhythmias (eg, patients with a history of prolonged QT, uncontrolled arrhythmias, recent MI, unstable angina, CHF, or cardiomyopathy). Consider pre-dose and post-colonoscopy ECGs in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fluid and electrolyte abnormalities: Fluid and electrolyte disturbances can lead to arrhythmias, seizures, and renal impairment. Advise patients to maintain adequate hydration before, during, and after treatment. If patient becomes dehydrated or experiences significant vomiting after treatment, consider post-colonoscopy lab tests (electrolytes, creatinine, and BUN).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ischemic colitis: Cases of ischemic colitis have been reported; concomitant use of stimulant laxatives may increase the risk and is not recommended.  The potential for mucosal aphthous ulcerations as a result of the bowel preparation should be considered, especially when evaluating colonoscopy results in patients with known or suspected inflammatory bowel disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizures: Generalized tonic-clonic seizures and/or loss of consciousness have occurred rarely in patients with no prior history of seizures. Seizures resolved with the correction of fluid and electrolyte abnormalities. Use with caution in patients with a history of seizures or who are at an increased risk of seizures (eg, concomitant administration of medications that lower the seizures threshold, patients withdrawing from alcohol or benzodiazepines) and in patients with known or suspected hyponatremia or low serum osmolality.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Impaired gag reflex: Observe unconscious or semiconscious patients with impaired gag reflex or those who are otherwise prone to regurgitation or aspiration during administration. Use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment and/or in patients taking medications that may adversely affect renal function (eg, diuretics, NSAIDs, ACE inhibitors, ARBs). Patients with impaired renal function should be instructed to remain adequately hydrated; consider pre-dose and post-colonoscopy lab tests (electrolytes, creatinine, BUN) in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Ulcerative colitis: Use with caution in patients with severe ulcerative colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in patients &gt;60 years of age; serious adverse events have been reported (eg, asystole, esophageal perforation, chest infiltration following vomiting and aspiration, Mallory-Weiss tear with GI bleeding, pulmonary edema with sudden dyspnea).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Use in patients &lt;2 years of age may result in hypoglycemia, dehydration, and hypokalemia; use with caution and monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; MoviPrep: Use with caution in patients with G6PD deficiency (especially patients with an active infection, history of hemolysis, or taking concomitant medications known to precipitate hemolytic reactions) due to the presence of sodium ascorbate and ascorbic acid in the formulation. Contains phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Evaluate patients with symptoms of bowel obstruction or perforation (nausea, vomiting, abdominal pain or distension) prior to use; if a patient develops severe bloating, distention or abdominal pain during administration, slow the rate of administration or temporarily discontinue use until the symptoms subside. Correct electrolyte abnormalities in patients prior to use. No additional ingredients or flavors (other than the flavor packets provided) should be added to the polyethylene glycol-electrolyte solution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299900\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6222413\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9789&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211100\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211113\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Information related to the use of polyethylene glycol-electrolyte solution in pregnancy is limited (Neri, 2004). Colonoscopy in pregnant women is generally reserved for strong indications or life-threatening emergencies; until additional safety data for polyethylene glycol-electrolyte solution is available, other agents may be preferred for this purpose (Siddiqui, 2006; Wexner, 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211114\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if polyethylene glycol-electrolyte solution is excreted into breast milk. Significant changes in the mother's fluid or electrolyte balance would not be expected with most products.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211115\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CoLyte, GaviLyte-C, GaviLyte-G, GaviLyte-N, GoLYTELY, NuLYTELY, TriLyte: Ideally, the patient should fast for ~3-4 hours prior to administration, but in no case should solid food be given for at least 2 hours before the solution is given. Some products contain aspartame which is metabolized to phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MoviPrep: Patient should not eat solid food from start of solution administration until after colonoscopy. Patient may have clear liquid soup/plain yogurt for dinner; finish at least 1 hour before start of colon prep. MoviPrep contains phenylalanine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211102\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Electrolytes, serum glucose, BUN, urine osmolality; children &lt;2 years of age should be monitored for hypoglycemia, dehydration, hypokalemia</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Whole bowel irrigation (off-label use; AACT, 2004): Rectal effluent (continue until clear or the poison is completely removed)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211093\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Induces catharsis by strong electrolyte and osmotic effects</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F211109\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">Onset of effect: Oral: ~1 hour</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4589209\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Colyte with Flavor Packs Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 g (4000 mL): $68.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (GaviLyte-C Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">240 g (4000 mL): $19.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (GaviLyte-G Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">236 g (4000 mL): $21.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (GaviLyte-N with Flavor Pack Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">420 g (4000 mL): $28.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Golytely Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">227.1 g (1): $15.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">236 g (4000 mL): $23.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (MoviPrep Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 g (1): $119.65</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Nulytely with Flavor Packs Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">420 g (4000 mL): $32.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (PEG 3350-KCl-Na Bicarb-NaCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">420 g (4000 mL): $22.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (TriLyte Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">420 g (4000 mL): $28.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29044095\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Barex (AR);</li>\n      <li>Cleargol (AU);</li>\n      <li>Coloclean (IN);</li>\n      <li>Colofort (BE, NL);</li>\n      <li>Colonsoft (FI);</li>\n      <li>Colopeg (IN);</li>\n      <li>CosmoCol (GB);</li>\n      <li>Delcoprep (DE);</li>\n      <li>Endofalk (BE, CL, DK, FI, NO, PT, RU, SE, UA);</li>\n      <li>Endopeg (IN);</li>\n      <li>Gangiden (DK);</li>\n      <li>Glycoprep (AU, NZ);</li>\n      <li>Golytely (TR);</li>\n      <li>GoLytely (ZA);</li>\n      <li>Icolon (IN);</li>\n      <li>Iscolan (CH);</li>\n      <li>Klean Prep (AT);</li>\n      <li>Klean-Prep (BE, CH, DE, ES, FR, GB, GR, HK, IT, LB, MT, NL, NZ, PT, QA, SG, ZA);</li>\n      <li>Laxacon (AU);</li>\n      <li>Laxido (FI, SE);</li>\n      <li>Macrovic (AU);</li>\n      <li>Meroken New (IL);</li>\n      <li>Molaxole (AT, CH, CY, EE, ES, GR, HU, IT, NL, NO, PT, SE, SK, TR);</li>\n      <li>Movicol (AE, AT, BE, CN, DE, DK, ES, FI, FR, GB, IN, IS, IT, JO, KW, LB, LK, MT, NO, NZ, PT, QA, SE, SG, VN, ZA);</li>\n      <li>Moviprep (AU, BB, CZ, EE, GB, HR, IS, JO, KW, LB, LT, LU, MT, NO, NZ, SA, SI);</li>\n      <li>Movyprep (UA);</li>\n      <li>Moxalole (DK, FI, FR, PL);</li>\n      <li>NuLytely (MX);</li>\n      <li>Oralav (DE);</li>\n      <li>Osmolax (AT);</li>\n      <li>Peglyte (SG);</li>\n      <li>ShuTaiQing (CN);</li>\n      <li>Transipeg (BE, CH, FR, RU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Clinical Toxicology, European Association of Poison Centres and Clinical Toxicologists, &ldquo;Position Paper: Whole Bowel Irrigation,&rdquo; <i>J Toxicol Clin Toxicol</i>, 2004, 42(6):843-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-electrolyte-solution-drug-information/abstract-text/15533024/pubmed\" target=\"_blank\" id=\"15533024\">15533024</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cappell MS, Fox SR, and Gorrepati N, &quot;Safety and Efficacy of Colonoscopy During Pregnancy: An Analysis of Pregnancy Outcome in 20 Patients,&quot; <i>J Reprod Med</i>,  2010, 55(3-4):115-23..<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-electrolyte-solution-drug-information/abstract-text/20506671 /pubmed\" target=\"_blank\" id=\"20506671 \">20506671 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chattopadhyay A, Prakash B, Vepakomma D, et al, &ldquo;A Prospective Comparison of Two Regimes of Bowel Preparation for Pediatric Colorectal Procedures: Normal Saline With Added Potassium vs Polyethylene Glycol,&rdquo; <i>Pediatr Surg Int</i>, 2004, 20(2):127-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-electrolyte-solution-drug-information/abstract-text/14752676/pubmed\" target=\"_blank\" id=\"14752676\">14752676</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    CoLyte (polyethylene glycol-electrolyte solution) [prescribing information]. Somerset, NJ: Meda; February 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    GaviLyte-G (PEG-3350 and electrolytes) [prescribing information]. Somerset, NJ: Gavis; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lo JC, Ubaldo C, and Cantrell FL, &quot;A Retrospective Review of Whole Bowel Irrigation in Pediatric Patients,&quot; <i>Clin Toxicol (Phila)</i>, 2012, 50(5):414-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-electrolyte-solution-drug-information/abstract-text/22578074/pubmed\" target=\"_blank\" id=\"22578074\">22578074</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neri I, Blasi I, Castro P, et al, &quot;Polyethylene Glycol Electrolyte Solution (Isocolan) for Constipation During  Pregnancy: An Observational Open-Label Study,&quot; <i>J Midwifery Womens Health</i>, 2004 , 49(4):355-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-electrolyte-solution-drug-information/abstract-text/15236717/pubmed\" target=\"_blank\" id=\"15236717\">15236717</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siddiqui U and Denise Proctor D, &quot;Flexible Sigmoidoscopy and Colonoscopy During Pregnancy,&quot; <i>Gastrointest Endosc Clin N Am</i>, 2006, 16(1):59-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-electrolyte-solution-drug-information/abstract-text/16546023/pubmed\" target=\"_blank\" id=\"16546023\">16546023</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sondheimer JM, Sokol RJ, Taylor SF, et al, &ldquo;Safety, Efficacy and Tolerance of Intestinal Lavage in Pediatric Patients Undergoing Diagnostic Colonoscopy,&rdquo; <i>J Pediatr</i>, 1991, 119(1):148-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-electrolyte-solution-drug-information/abstract-text/2066847/pubmed\" target=\"_blank\" id=\"2066847\">2066847</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tuggle DW, Hoelzer DJ, Tunell WP, et al, &ldquo;The Safety and Cost-Effectiveness of Polyethylene Glycol Electrolyte Solution Bowel Preparation in Infants and Children,&rdquo; <i>J Pediatr Surg</i>, 1987, 22(6):513-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-electrolyte-solution-drug-information/abstract-text/3112357/pubmed\" target=\"_blank\" id=\"3112357\">3112357</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wexner SD, Beck DE, Baron TH, et al,  &ldquo;A Consensus Document on Bowel Preparation Before Colonoscopy: Prepared by a Task Force from The American Society of Colon and Rectal Surgeons (ASCRS), The American Society for Gastrointestinal and Endoscopy (ASGE) and The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES),&rdquo; <i>Dis Colon Rectum</i>, 2006, 49(6):792-809.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-electrolyte-solution-drug-information/abstract-text/16649119/pubmed\" target=\"_blank\" id=\"16649119\">16649119</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9789 Version 91.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F211122\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F211123\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F211139\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F211125\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F211134\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F211126\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F22448429\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22448430\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F211104\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F211090\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F12808915\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F211107\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F211105\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25470743\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F211145\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F211097\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F211110\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F211094\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299900\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6222413\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F211100\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F211113\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F211114\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F211115\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F211102\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F211093\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F211109\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F4589209\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F29044095\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9789|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=polyethylene-glycol-electrolyte-solution-patient-drug-information\" class=\"drug drug_patient\">Polyethylene glycol electrolyte solution: Patient drug information</a></li><li><a href=\"topic.htm?path=polyethylene-glycol-electrolyte-solution-pediatric-drug-information\" class=\"drug drug_pediatric\">Polyethylene glycol electrolyte solution: Pediatric drug information</a></li></ul></div></div>","javascript":null}